Coprescription of Triptans With Potentially Interacting Medications: A Cohort Study Involving 240 268 Patients

Abstract

Triptan use mirrors migraine demographics. The frequency of co-prescription of triptans with SSRIs is about 20%. Continued vigilance will be necessary to avoid co-prescription of medicines with the potential for producing adverse drug events.